Cyclacel Pharmaceuticals, Inc. (NASDAQ:BGMS) Shares Shorted: Short Interest Up 440.0% in October

Cyclacel Pharmaceuticals, Inc. (NASDAQ:BGMS) was the target of a significant growth in short interest in October. As of October 15th, there was short interest totaling 30,190 shares, a growth of 440.0% from the September 30th total of 5,591 shares. Based on an average daily volume of 39,784 shares, the short-interest ratio is presently 0.8 days. Approximately 0.7% of the shares of the company are sold short.

Analyst Ratings Changes

Separately, Weiss Ratings upgraded shares of Cyclacel Pharmaceuticals from a “sell (e)” rating to a “sell (e+)” rating in a research note on Wednesday, July 29th. One investment analyst has rated the stock with a Sell rating. Based on data from MarketBeat.com, Cyclacel Pharmaceuticals has a consensus rating of “Sell”.

Cyclacel Pharmaceuticals Stock Performance

Cyclacel Pharmaceuticals stock traded down $0.01 during midday trading on Tuesday, reaching $0.94. The company’s stock had a trading volume of 334 shares, compared to its average volume of 764,851. Cyclacel Pharmaceuticals has a fifty-two week low of $0.57 and a fifty-two week high of $2.80. The stock’s 50 day simple moving average is $0.90 and its 200 day simple moving average is $0.98. The firm has a market capitalization of $5.20 million, a PE ratio of -0.26 and a beta of -0.39.

Cyclacel Pharmaceuticals (NASDAQ:BGMS) last announced its quarterly earnings results on Friday, August 14th. The company reported ($0.08) EPS for the quarter. The firm had revenue of $0.34 million for the quarter. Cyclacel Pharmaceuticals had a negative return on equity of 31.60% and a negative net margin of 118.27%.

Cyclacel Pharmaceuticals Company Profile

Cyclacel Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on developing targeted medicines for the treatment of cancer. Its research programs center on small-molecule therapies designed to interfere with key cell-cycle and transcription processes involved in tumor growth.

The company’s pipeline has included fadraciclib (CYC065), an oral cyclin-dependent kinase inhibitor being studied for advanced solid tumors and hematologic malignancies. Cyclacel has also developed sapacitabine (CYC682), an oral nucleoside analog, and seliciclib (CYC202), an earlier-stage cyclin-dependent kinase inhibitor.